BACKGROUND The Fibroblast Growth Factor Receptor-1 (FGFR-1) is a tyrosine kinase and a validated target for treatment of different cancer types. OBJECTIVE Design and synthesis of novel thiazole-based analogues of… Click to show full abstract
BACKGROUND The Fibroblast Growth Factor Receptor-1 (FGFR-1) is a tyrosine kinase and a validated target for treatment of different cancer types. OBJECTIVE Design and synthesis of novel thiazole-based analogues of anticancer agents. METHODS Series of 2-aryl-5-methylthiazole analogues linked to structurally variable basic heads were synthesized as novel anticancer agents. Developed compounds were tested for their cytotoxic activities against several cancer cell lines. RESULTS Many analogues exhibited strong antiproliferative activities against breast cancer cell lines, with higher potency towards the highly metastatic form (MDA-MB-231). Pharmacophoric profiling using in-house pharmacophore database identified FGFR-1 as a molecular target of active analogues. Synthesized compounds were bioassayed for their FGFR-1 inhibitory activities and many hits exhibited IC50 values in the low micromolar to nanomolar range. CONCLUSION The 2-aryl-5-methylthiazole linked to a basic head is a novel chemical scaffold of ATP-competitive inhibitor of FGFR-1 with potential therapeutic activities against different types of cancer.
               
Click one of the above tabs to view related content.